[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360121-105":59,"doc-detail-360121-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","effect-of-obesity-and-endocrine-therapy-on-the-prognosis-of-premenopausal-women-with-hrher2-breast-cancer-a-multicenter-retrospective-study","Effect of obesity and endocrine therapy on the prognosis of premenopausal women with HR+HER2-breast cancer: a multicenter retrospective study","","Obesity’s influence on breast cancer outcomes may vary by molecular subtype, and evidence for premenopausal women with HR+HER2 early-stage disease remains limited. A multicenter retrospective study analyzed 5,094 such patients treated with radical surgery across 42 breast centers in China (2016–2021). After propensity score matching and survival analyses, obesity showed a worse disease-free survival pattern, remaining an independent prognostic factor in HR+/HER2- patients, with OFS potentially attenuating obesity’s adverse effect.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/effect-of-obesity-and-endocrine-therapy-on-the-prognosis-of-premenopausal-women-with-hrher2-breast-cancer-a-multicenter-retrospective-study/360121/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/effect-of-obesity-and-endocrine-therapy-on-the-prognosis-of-premenopausal-women-with-hrher2-breast-cancer-a-multicenter-retrospective-study/360121.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"How many premenopausal patients were included, and when were they treated?","Question",{"text":112,"@type":113},"The study included 5,094 premenopausal women with HR+HER2 early-stage breast cancer, who underwent radical surgery at 42 centers in China between 2016 and 2021.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What survival endpoint was used to evaluate prognosis by BMI?",{"text":117,"@type":113},"Disease-free survival (DFS) was compared across BMI categories using Kaplan–Meier curves, with further evaluation by multivariate Cox regression after propensity score matching.",{"name":119,"@type":110,"acceptedAnswer":120},"Does obesity remain a prognostic factor after adjusting for clinical and treatment variables?",{"text":121,"@type":113},"Yes. After adjustment for clinicopathologic factors and treatment, obesity remained an independent prognostic factor for DFS in premenopausal HR+/HER2- patients.",{"name":123,"@type":110,"acceptedAnswer":124},"How might ovarian function suppression (OFS) affect the impact of obesity in patients treated with SERMs?",{"text":125,"@type":113},"The findings suggest OFS may attenuate the detrimental effect of obesity among patients treated with selective estrogen receptor modulators (SERMs).","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},360121,1790185437,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEffect of obesity and endocrine therapy on the prognosis of premenopausal women with HR+HER2-breast cancer: a multicenter retrospective study  \nWeibin Lian1,2􀀍, Chengye Hong1, Chuan Wang2􀀍 & Debo Chen1􀀍  \nObesity’s impact on breast cancer prognosis may depend on molecular subtype, yet there is limited research on premenopausal women with HR+HER2-breast cancer. In this study, we included 5,094 premenopausal women with HR+HER2-early-stage breast cancer who underwent radical surgery at 42 breast centers across China between 2016 and 2021. Patients were categorized into four BMI groups: underweight (UW), normal weight (NW), overweight (OW), and obese (OB). Using propensity score matching (PSM) to adjust for confounding factors, we compared disease-free survival (DFS) across BMI groups with Kaplan–Meier curves and performed multivariate Cox regression analysis to evaluate the effect of obesity on prognosis. Our results showed that obese patients had significantly worse DFS compared to those who were UW, NW, or OW (p = 0.013). After adjusting for clinicopathologic factors and treatment, obesity remained an independent prognostic factor for DFS in premenopausal HR+/HER2-patients (p = 0.043). After 1:1 PSM, OW/OB patients receiving selective estrogen receptor modulators (SERMs) alone had significantly worse DFS compared to UW/NW patients (p = 0.022), whereas OW/OB patients treated with SERMs or aromatase inhibitors (AIs) in combination with ovarian function suppression (OFS) showed no significant difference in DFS from UW/NW patients. In addition, Restricted Cubic Splines (RCS) analysis demonstrated that the risk of recurrence increases with BMI in OW/OB patients. Collectively, these findings indicate that obesity may act as an independent adverse prognostic factor for DFS in premenopausal women with HR+/HER2− breast cancer. Importantly, our results also suggest that OFS may attenuate the detrimental effect of obesity in patients treated with SERMs.  \nKeywords Obesity, Prognosis, Breast cancer, Premenopausal  \nBody mass index (BMI), a widely used metric for categorizing weight and obesity, has been implicated in breast cancer incidence. Studies have demonstrated that obesity increases the risk of type 2 diabetes mellitus by promoting insulin resistance and elevates serum estrogen levels through the upregulation of aromatase. Elevated circulating glucose has also been shown to activate the mammalian target of rapamycin (mTOR), a key signaling pathway in breast cancer pathogenesis1. A growing body of research has explored the association between BMI and prognosis in early-stage breast cancer. A meta-analysis of 73 cohort studies found that being overweight or obese is a risk factor for overall survival (OS) in breast cancer patients compared to those of normal weight2. However, the relationship between obesity and breast cancer prognosis remains variable and controversial across different molecular subtypes and menopausal statuses. A prospective randomized controlled trial identified obesity as an independent prognostic factor in estrogen receptor-positive (ER +) breast cancer in younger patients but not in ER-negative disease3. Similarly, an analysis by Sparano et al., based on multiple prospective randomized controlled trials, found that higher BMI within the overweight (OW) and obese (OB) categories was associated with poorer disease-free survival (DFS) and OS in hormone receptor-positive, HER2-negative  \n1Department of Breast Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, Fujian, People’s Republic of China. 2Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou 350000, Fujian, People’s Republic of China. 􀀍 email: [weibinlian@fjmu.edu.cn](weibinlian@fjmu.edu.cn);  \n[dr_chuanwang@fjmu.edu.cn](dr_chuanwang@fjmu.edu.cn); [debochensr@fjmu.edu.cn](debochensr@fjmu.edu.cn)  \n[www. nature.com/sc","cbCaisG7aqxhvEme","https://ap.wps.com/l/cbCaisG7aqxhvEme","pdf",2213512,"English","# Background and rationale\n# Study design and patient grouping\n## Statistical methods (PSM, Kaplan–Meier, Cox regression, RCS)\n# Results across BMI categories\n## Effects by endocrine therapy regimens\n# Interpretation and clinical implications","[{\"question\":\"How many premenopausal patients were included, and when were they treated?\",\"answer\":\"The study included 5,094 premenopausal women with HR+HER2 early-stage breast cancer, who underwent radical surgery at 42 centers in China between 2016 and 2021.\"},{\"question\":\"What survival endpoint was used to evaluate prognosis by BMI?\",\"answer\":\"Disease-free survival (DFS) was compared across BMI categories using Kaplan–Meier curves, with further evaluation by multivariate Cox regression after propensity score matching.\"},{\"question\":\"Does obesity remain a prognostic factor after adjusting for clinical and treatment variables?\",\"answer\":\"Yes. After adjustment for clinicopathologic factors and treatment, obesity remained an independent prognostic factor for DFS in premenopausal HR+/HER2- patients.\"},{\"question\":\"How might ovarian function suppression (OFS) affect the impact of obesity in patients treated with SERMs?\",\"answer\":\"The findings suggest OFS may attenuate the detrimental effect of obesity among patients treated with selective estrogen receptor modulators (SERMs).\"}]","Effect of obesity and endocrine therapy on the prognosis of premenopausal women with HR+HER2-breast cancer: a multicenter retrospective study | PDF",1790138800,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e033629f721d72c6fee95f4c7d083ec0.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/319da19a37b9aa62d80eb291cc2fad5f.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9b17ce5def693f696b5097b1041289e.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa18e36459e24b1f1b9161a268f6394c.webp",980,1287]